News

Childhood trauma, cannabis use disorders examined in schizophrenia


 

FROM SCHIZOPHRENIA RESEARCH

References

New findings suggest childhood trauma and cannabis use disorders have no significant interaction in outcomes for patients with schizophrenia, according to Grégoire Baudin and his associates.

skydie/ThinkStock

The researchers recruited 366 people aged 15-84 years. Two hundred ninety-five of the subjects (80.6%) met the DSM-IV-TR criteria for schizophrenia, and 71 (19.4%) for schizoaffective disorder. They found that 30.49% of the patients reported at least one significant childhood trauma, and 13.77% reported two or more. The proportion of patients reporting childhood traumas were comparable by gender; 33.78% of women and 33% of men reported at least one trauma. The differences between those rates were not statistically significant (P = 0.449), the researchers reported. Among patients with cannabis use disorders, 99 (27.05%) had a lifetime diagnosis of cannabis use disorder. This diagnosis significantly predicted age of onset, age at first hospitalization, and Medication Adherence Rating Scale scores.

Overall, no significant interaction was found between childhood trauma and cannabis use disorders. However, after adjustment for age and gender, a correlation was found (P = 0.004). But “the proportion of patients with a history of trauma among subjects with and without cannabis use disorders did not significantly differ,” the researchers wrote (P = 0.278).

“Our results emphasize the need for clinicians to systematically inquire about the traumatic history of patients with psychotic disorders, and consider trauma-focused therapy” for people with schizophrenia and those at risk, researchers concluded.

Read the full study in Schizophrenia Research (doi: 10.1016/j.schres.2016.04.042).

llaubach@frontlinemedcom.com

Recommended Reading

Psychosis: First-episode variety in adolescence ‘insidious’
MDedge Family Medicine
Psychosis: Watch for sudden poor academic performance
MDedge Family Medicine
VIDEO: Lifestyle intervention blocks antipsychotic-associated weight gain
MDedge Family Medicine
Prepsychosis links with elevated metabolic syndrome
MDedge Family Medicine
Suicidal ideation: An 18-year-old male presents in crisis
MDedge Family Medicine
Suicidal ideation: Team-based care requires knowledge, resources
MDedge Family Medicine
FDA approves first drug to treat hallucinations in Parkinson’s psychosis
MDedge Family Medicine
Aripiprazole linked to rare but serious compulsion problems
MDedge Family Medicine
FDA: Olanzapine can cause serious skin reaction
MDedge Family Medicine
VIDEO: Integrated care effective in first-episode psychosis
MDedge Family Medicine